Using Ibrutinib in Chronic Lymphocytic Leukemia (CLL)

(7:13)

CLL: Optimal approaches for patients with deletion 17p

(21:5)

Crafting the New Treatment Mix in CLL

(58:11)

How Long Can I Live with CLL? (Chronic Lymphocytic Leukemia) | The Patient Story

(5:24)

Ibrutinib resistance-mechanisms and options in CLL

(29:14)

Treatment options for the young CLL patient with deletion 17p: Do they need a different approach?

(19:42)

CLL: The Risk of Richter’s Transformation

(10:14)

Sonrotoclax \u0026 zanubrutinib as frontline treatment for CLL: data from the BGB-11417-101 study

(1:29)

FOCUS ON Cytogenomics: Chronic Lymphocytic Leukaemia (CLL) 25th October 2022

(54:53)

Comparability of next generation gene panel assays in CLL

(2:48)

Debate: Optimal approach for the management of CLL patients with del(17p) - Novel Agents

(13:55)

What is flow cytometry? #CLL

(1:23)

Familial CLL: Increasing?

(22:27)

Chronic Lymphocytic Leukemia: MRD Updates

(26:34)

CLL panel discussion about exercise and nutrition

(57:56)

CAR-T Cell Therapies in CLL

(4:52)

New Anti-CD20 Antibodies for CLL - Are They Better than Rituximab?

(21:17)

Minimal residual disease (MRD) in CLL: Is it clinically relevant?

(21:9)

What CLL Tests Are Essential and How Do Results Impact Treatment and Prognosis?

(7:29)

Introduction: Upfront Treatment in Patients with Chronic Lymphocytic Leukemia (CLL)

(9:39)